Physician profile
Max R Kates
NPI 1487910600
$139,005.66
in general payments reported to CMS, 2019-2025
17 companies · $77K in 2025
The $77K reported for 2025 was more than what 99% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,922 · 2020: $1,635 · 2021: $1,500 · 2022: $20K · 2023: $10K · 2024: $24K · 2025: $77K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $101K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,500 · Travel and Lodging: $2,580 · Honoraria: $2,400 · Food and Beverage: $1,232 · Education: $60.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $100,927.35 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,500.00 |
| Travel and Lodging | $2,580.05 |
| Honoraria | $2,400.00 |
| Food and Beverage | $1,231.86 |
| Education | $60.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urogen Pharma, INC. | $80,701.88 | 2022-2025 | |
| Photocure INC | $13,875.00 | 2022-2023 | Cysview |
| Pfizer INC. | $9,686.60 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $7,863.60 | 2022-2025 | Keytruda |
| Astellas Pharma Global Development | $5,900.00 | 2022-2024 | Padcev |
| Seagen INC. | $4,550.00 | 2021-2023 | Padcev |
| Janssen Global Services, LLC | $4,150.00 | 2020-2025 | |
| Intuitive Surgical, INC. | $4,006.82 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $2,540.06 | 2025 | Imfinzi |
| Immunitybio, INC. | $2,400.00 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,950.00 | 2022 | |
| Olympus Winter & Ibe Gmbh | $1,080.00 | 2024 | Single Use Repositionable Clip |
| Olympus America INC. | $168.57 | 2022 | |
| Ethicon US, LLC | $114.30 | 2024-2025 | Enseal X1, Echelon Flex |
| Ferring Pharmaceuticals INC. | $18.83 | 2024 | Adstiladrin |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Max Kates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.